{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:03:11Z","timestamp":1761854591705,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.pathol.2020.01.679","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T18:53:21Z","timestamp":1582570401000},"page":"377-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metachronous chronic myeloid leukaemia occurring with background multiple myeloma"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-2667","authenticated-orcid":false,"given":"James","family":"Yeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liane","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2020.01.679_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2020.01.679_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clml.2012.09.010","article-title":"A\u00a0case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature","volume":"13","author":"Ragupathi","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2020.01.679_bib3","first-page":"152","article-title":"Pleural effusion as the initial manifestation of chronic myeloid leukemia: report of a case with clinical and cytologic correlation","volume":"29","author":"Nuwal","year":"2012","journal-title":"J\u00a0Cytol"},{"key":"10.1016\/j.pathol.2020.01.679_bib4","first-page":"170","article-title":"Multiple myeloma preceding the development of chronic myelogenous leukemia","volume":"69","author":"Nitta","year":"1999","journal-title":"Int J Hematol"},{"key":"10.1016\/j.pathol.2020.01.679_bib5","first-page":"7863943","article-title":"An unprecedented case of p190 BCR-ABL chronic myeloid leukemia diagnosed during treatment for multiple myeloma: a case report and review of the literature","volume":"2018","author":"Miki","year":"2018","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.pathol.2020.01.679_bib6","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.18632\/oncotarget.23971","article-title":"Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for \u201cpersonalized monitoring\u201d of residual disease in chronic myeloid leukemia patients","volume":"9","author":"Cumbo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2020.01.679_bib7","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2020.01.679_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.2013.097907","article-title":"Understanding the multiple biological aspects leading to myeloma","volume":"99","author":"Boyle","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2020.01.679_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2020.01.679_bib10","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1182\/blood.V122.21.5172.5172","article-title":"Imatinib (IM) plus thalidomide (Thali), a effective combination for the treatment of chronic myeloid leukemia (CML) Philadelphia chromosomepositive (Ph\u00a0+) in IM-resistant disease. Report of 14 new cases from a single center in Mexico","volume":"122","author":"Hurtado Monroy","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2020.01.679_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.13346","article-title":"Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era","volume":"169","author":"Gunnarsson","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2020.01.679_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520307133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520307133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:25:59Z","timestamp":1758471959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302520307133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0031302520307133"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2020.01.679","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metachronous chronic myeloid leukaemia occurring with background multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2020.01.679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}